Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base

Annals of Surgical Oncology

Volumn 22, Issue 10, 2015, Pages 3264-3272

  Flanagan, Meghan R ^a   Rendi, Mara H ^b   Gadi, Vijayakrishna K ^b,c   Calhoun, Kristine E ^a   Gow, Kenneth W ^a,d   Javid, Sara H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COHORT ANALYSIS; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FOLLOW UP; MASTECTOMY; METABOLISM; PATHOLOGY; PROGNOSIS; TIME FACTOR; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84940449079     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4668-z     Document Type: Article

References (36)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.
2. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.
3. Wehner P, Lagios MD, Silverstein MJ. DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines. Ann Surg Oncol. 2013;20:3175–9.
4. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.
5. Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006;192:416–9.
6. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 2011;129:929–38.
7. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.
8. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, Breast Cancer (Version 2.2013). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 Aug 2014.
10. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.
11. Ceilley E, Jagsi R, Goldberg S, Kachnic L, Powell S, Taghian A. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer. 2004;101:1958–67.
12. Livaudais JC, Hwang ES, Karliner L, et al. Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health. 2012;21:35–42.
13. Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg. 2005;201:688–94.
14. Yen TWF, Kuerer HM, Ottesen RA, et al. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol. 2007;25:3251–8.
15. Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer. 2006;106:2113–8.
16. Virnig BA, Torchia MT, Jarosek SL, Durham S, Tuttle TM. Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer. Data Points 14. Rockville: Agency for Healthcare Research and Quality; 2011.
17. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.
18. Schafer J. Analysis of incomplete multivariate data. London: Chapman and Hall; 1997.
19. Rubin DB. Inference and missing data. Biometrika. 1976;63:581–92.
20. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940–3.
21. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor–positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30:1268–73.
22. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.
23. Jackson LC, Camacho F, Levine EA, Anderson RT, Stewart JH. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. Am J Surg. 2008;195:164–9.
24. Feigelson HS, Carroll NM, Weinmann S, et al. Treatment patterns for ductal carcinoma in situ from 2000–2010 across six integrated health plans. Springerplus. 2015;4:24.
25. Haque R, Achacoso NS, Fletcher SW, et al. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010;16:351–60.
26. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986;57:197–208.
27. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137–46.
28. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.
29. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300.
30. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.
31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.
32. Javid SH, He H, Korde LA, Flum DR, Anderson BO. Predictors and outcomes of completion axillary node dissection among older breast cancer patients. Ann Surg Oncol. 2014;21:2172–80.
33. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.
34. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.
35. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference Statement. Diagnosis and management of ductal carcinoma in situ, September 22–24, 2009. J Natl Cancer Inst. 2010;102:161–9.
36. Friese CR, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013;138:931–9.